Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMP-3124LP phase 1/2 study in advanced solid tumors
jRCT2031240272Phase 2Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Sep 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, open-label trial of smp-3124lp in advanced nonhematological malignancy, ovarian cancer, fallopian tube cancer (PFTC) and 6 more (4 arms), sponsored by Sumitomo Pharma. Primary endpoints: Recommended phase 2 dose, Safety and tolerability and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
smp-3124lp
03
Conditions
advanced nonhematological malignancyovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031240272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240272.